The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study

Author:

Sozeri BetulORCID,Ulu KadirORCID,Kaya-Akça UmmusenORCID,Haslak FatihORCID,Pac-Kisaarslan AysenurORCID,Otar-Yener GulcinORCID,Baba OzgeORCID,Altug-Gucenmez OzgeORCID,Sahin NihalORCID,Bağlan EsraORCID,Sönmez Hafize EmineORCID,Cakmak FigenORCID,Ozturk KubraORCID,Gezgin-Yıldırım DenizORCID,Şener SeherORCID,Barut KenanORCID,Batu Ezgi DenizORCID,Yıldız MehmetORCID,Basaran OzgeORCID,Adrovic AmraORCID,Sahin SezginORCID,Ozdel SemanurORCID,Bilginer YeldaORCID,Poyrazoglu Muammer HakanORCID,Demir FerhatORCID,Yuksel SelcukORCID,Kalyoncu MukaddesORCID,Kasapcopur OzgurORCID,Ozen SezaORCID,Aktay-Ayaz NurayORCID

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference16 articles.

1. World Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on February 12, 2020)

2. World Health Organization (WHO). WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020 (Accessed on May 01, 2020)

3. World Health Organization https://www.who.int/emergencies/diseases/novel-coronavirus-2019

4. Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva E et al (2018) Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from pharmachild and national registries. Arthritis Res Ther 20:285

5. Akiyama S, Hamdeh S, Micic D, Sakuraba A (2021) Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis 80:384–391

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3